ATE457318T1 - Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper - Google Patents

Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper

Info

Publication number
ATE457318T1
ATE457318T1 AT01273341T AT01273341T ATE457318T1 AT E457318 T1 ATE457318 T1 AT E457318T1 AT 01273341 T AT01273341 T AT 01273341T AT 01273341 T AT01273341 T AT 01273341T AT E457318 T1 ATE457318 T1 AT E457318T1
Authority
AT
Austria
Prior art keywords
directed against
human bst2
monoclonal antibod
bst2 antigen
antigen
Prior art date
Application number
AT01273341T
Other languages
English (en)
Inventor
Tomoyuki Tahara
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ATE457318T1 publication Critical patent/ATE457318T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01273341T 2000-12-28 2001-12-26 Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper ATE457318T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000403245 2000-12-28
PCT/JP2001/011493 WO2002057316A1 (en) 2000-12-28 2001-12-26 Novel monoclonal antibody

Publications (1)

Publication Number Publication Date
ATE457318T1 true ATE457318T1 (de) 2010-02-15

Family

ID=18867405

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01273341T ATE457318T1 (de) 2000-12-28 2001-12-26 Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper

Country Status (6)

Country Link
US (1) US7592005B2 (de)
EP (1) EP1354896B1 (de)
JP (1) JP4450555B2 (de)
AT (1) ATE457318T1 (de)
DE (1) DE60141297D1 (de)
WO (1) WO2002057316A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CN101087611B (zh) * 2003-10-10 2019-04-23 伊缪诺金公司 用经不可切割接头连接的细胞结合剂美登木素生物碱偶联物靶向特定细胞群的方法、所述偶联物和制备所述偶联物的方法
EP1767625A4 (de) * 2004-06-11 2007-12-05 Ginkgo Biomedical Res Inst Co Aktivitätsregulator für interferonproduzierende zelle
US20100143899A1 (en) * 2005-05-17 2010-06-10 University Of Vermont And State Agricultural College Methods and products for diagnosing cancer
WO2008036688A2 (en) * 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
WO2008134020A1 (en) * 2007-04-26 2008-11-06 University Of Vermont And State Agricultural College Ccl18 and ccl3 methods and compositions for detecting and treating cancer
KR20100090258A (ko) 2007-10-16 2010-08-13 에스비아이 바이오테크 가부시키가이샤 항bst2 항체
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
BRPI0913045A2 (pt) * 2008-05-23 2017-05-23 Fit Biotech Oy vetor de expressão codificador de alfa-vírus replicase e uso do mesmo como adjuvante imunológico
ES2602971T3 (es) 2010-03-02 2017-02-23 Kyowa Hakko Kirin Co., Ltd. Composición de anticuerpo modificado
US20130259878A1 (en) * 2010-10-20 2013-10-03 Oxford Biotherapeutics Ltd Antibodies
CN107619443B (zh) * 2016-07-14 2020-08-14 深圳宾德生物技术有限公司 抗人和鼠cd317的单克隆抗体及其制备方法和应用
WO2018158716A1 (en) 2017-03-02 2018-09-07 Cadila Healthcare Limited Novel protein drug conjugate formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
ATE297219T1 (de) * 1997-02-12 2005-06-15 Chugai Pharmaceutical Co Ltd Antikörper als arzneimittel gegen lymphocytische tumore (ausschliesslich myelome)
AU718463B2 (en) 1997-02-28 2000-04-13 Chugai Seiyaku Kabushiki Kaisha Inhibitor of lymphocyte activation
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JPH1192399A (ja) * 1997-09-24 1999-04-06 Chugai Pharmaceut Co Ltd 骨髄腫治療剤
EP1757941B1 (de) 1998-02-25 2010-03-31 Chugai Seiyaku Kabushiki Kaisha Verfahren zum immunochemischen Testen des Anti-HM1.24-Antikörpers

Also Published As

Publication number Publication date
EP1354896A4 (de) 2004-06-16
JP4450555B2 (ja) 2010-04-14
DE60141297D1 (de) 2010-03-25
US7592005B2 (en) 2009-09-22
EP1354896A1 (de) 2003-10-22
JPWO2002057316A1 (ja) 2004-05-20
WO2002057316A1 (en) 2002-07-25
EP1354896B1 (de) 2010-02-10
US20040136982A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
CY2020003I1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
ATE457318T1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
ATE389721T1 (de) Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen
DE60142342D1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
DE60029115D1 (de) Antigen enthaltende pharmazeutische zusammensetzung
EE05309B1 (et) β-Amloidpeptiidi „ratundvad humaniseeritud antikehad, meetod nende valmistamiseks, nende kasutamine ja farmatseutiline kompositsioon
UY26807A1 (es) Anticuerpos de especificidad doble y métodos para la elaboración y el uso de los mismos
CR20120505A (es) Composición de fármaco conjugado
EA200100224A1 (ru) Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
IS6779A (is) Mannlíkt mótefni gegn LT-beta-R
MY162623A (en) Immunoglobulin formulation and method of preparation thereof
FI1897548T4 (fi) T-solujen säätely
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
IT1318370B1 (it) Metodo e dispositivo per la diagnosi e la terapia dello scompensocardiaco cronico.
DE60138102D1 (de) Antikörper gegen menschliches mcp-1
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
ATE407147T1 (de) Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein
EP1542721A4 (de) Modifizierte "s" antikörper
EE200100366A (et) Antikehade kasutamine vähivastase farmatseutilisekompositsiooni valmistamiseks
GB0008305D0 (en) Treatment of fungal infections
DE69528624D1 (de) Anti-Fas Antikörper gegen rheumatische Krankheiten
EP1178829A4 (de) Menschlicher monoklonaler antikörper
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
TR200102877T2 (tr) İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties